Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis

BACKGROUND: Management of moderate-to-severe atopic dermatitis (AD) commonly requires long-term treatment. OBJECTIVE: The aim of this study was to report the safety and efficacy of dupilumab treatment for up to 3 years in adults with moderate-to-severe AD. METHODS: This ongoing, multicenter, open-la...

Descripción completa

Detalles Bibliográficos
Autores principales: Beck, Lisa A., Thaçi, Diamant, Deleuran, Mette, Blauvelt, Andrew, Bissonnette, Robert, de Bruin-Weller, Marjolein, Hide, Michihiro, Sher, Lawrence, Hussain, Iftikhar, Chen, Zhen, Khokhar, Faisal A., Beazley, Bethany, Ruddy, Marcella, Patel, Naimish, Graham, Neil M. H., Ardeleanu, Marius, Shumel, Brad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7371647/
https://www.ncbi.nlm.nih.gov/pubmed/32557382
http://dx.doi.org/10.1007/s40257-020-00527-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7371647/
https://www.ncbi.nlm.nih.gov/pubmed/32557382
http://dx.doi.org/10.1007/s40257-020-00527-x

Ejemplares similares